Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts (Nature Communications (2017) 8 (14864) DOI: 10.1038/ncomms14864);Proteogenomic integration reveals therapeutic targets in breast cancer xenografts

Nature Communications

Volumn 8, Issue , 2017, Pages

  Huang, Kuan Lin ^a   Li, Shunqiang ^a   Mertins, Philipp ^b   Cao, Song ^a   Gunawardena, Harsha P ^c   Ruggles, Kelly V ^d   Mani, D R ^b   Clauser, Karl R ^b   Tanioka, Maki ^e   Usary, Jerry ^e   Kavuri, Shyam M ^f   Xie, Ling ^c   Yoon, Christopher ^a   Qiao, Jana W ^b   Wrobel, John ^c   Wyczalkowski, Matthew A ^a   Erdmann Gilmore, Petra ^a   Snider, Jacqueline E ^a   Hoog, Jeremy ^a   Singh, Purba ^f   Niu, Beifung ^a   Guo, Zhanfang ^a   Sun, Sam Qiancheng ^a   Sanati, Souzan ^g   Kawaler, Emily ^d   Wang, Xuya ^d   Scott, Adam ^a   Ye, Kai ^a   McLellan, Michael D ^a   Wendl, Michael C ^a,g   Malovannaya, Anna ^f   Held, Jason M ^a,h   Gillette, Michael A ^b   Fenyö, David ^d   Kinsinger, Christopher R ⁱ   Mesri, Mehdi ⁱ   Rodriguez, Henry ⁱ   Davies, Sherri R ^a   Perou, Charles M ^e   Ma, Cynthia ^a,h   Reid Townsend, R ^a,h   Chen, Xian ^c   Carr, Steven A ^b   Ellis, Matthew J ^f   Ding, Li ^a,h   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g WASHINGTON UNIVERSITY   (United States)

^h Washington University in St Louis School of Medicine   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A RAF KINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HSP90AB1 PROTEIN; LAPATINIB; MESSENGER RNA; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SAPANISERTIB; SERABELISIB; TRASTUZUMAB; UNCLASSIFIED DRUG; TRANSCRIPTOME;

BIOMARKER; DRUG; ENZYME; ENZYME ACTIVITY; EXPERIMENTAL DESIGN; GENE EXPRESSION; GENOMICS; MASS SPECTROMETRY; NUMERICAL MODEL; PROTEIN; PROTEOMICS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOGENOMICS; PROTEOMICS; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENETICS; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEOGENOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016396817     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15479     Document Type: Erratum

References (51)

1. Green, E. D. & Guyer, M. S. National Human Genome Research, I. Charting a course for genomic medicine from base pairs to bedside. Nature 470, 204-213 (2011).
2. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
3. Rubio-Perez, C. et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 27, 382-396 (2015).
4. Simon, R. & Roychowdhury, S. Implementing personalized cancer genomics in clinical trials. Nat. Rev. Drug Discov. 12, 358-369 (2013).
5. Chin, L., Andersen, J. N. & Futreal, P. A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297-303 (2011).
6. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130 (2013).
7. Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338-350 (2012).
8. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
9. Holton, P. et al. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann. Hum. Genet. 77, 85-105 (2013).
10. Brown, K. E. et al. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. J. Neurochem. 133, 730-738 (2015).
11. Li, H. et al. Proteomic characterization of head and neck cancer patient-derived xenografts. Mol. Cancer Res. 14, 278-286 (2016).
12. Kim, M. S. et al. A draft map of the human proteome. Nature 509, 575-581 (2014).
13. Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382-387 (2014).
14. Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 (2016).
15. Zhang, H. et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166, 755-765 (2016).
16. Rauniyar, N. & Yates, 3rd J. R. Isobaric labeling-based relative quantification in shotgun proteomics. J. Proteome Res. 13, 5293-5309 (2014).
17. Bondarenko, G. et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia 17, 735-741 (2015).
18. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30 (2000).
19. Prat, A. & Perou, C. M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 5, 5-23 (2011).
20. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418-8423 (2003).
21. Croft, D. et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42, D472-D477 (2014).
22. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
23. Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901-5911 (2010).
24. Edkins, S. et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol. Ther. 5, 928-932 (2006).
25. Paik, S., Kim, C. & Wolmark, N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N. Engl. J. Med. 358, 1409-1411 (2008).
26. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A. & Greene, M. I. Down- modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
27. Carter, P. etal. Humanization ofan anti-p185HER2 antibodyfor human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
28. Witters, L. et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 68, 7083-7089 (2008).
29. Medina, P. J. & Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30, 1426-1447 (2008).
30. Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009).
31. Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012).
32. Mayer, I. A. et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 32, 1202-1209 (2014).
33. Bendell, J. C. et al. Phase I, dose-escalation studyofBKM120, an oralpan-Class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282-290 (2012).
34. Zhang, H. et al. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Res. 16, R36 (2014).
35. Xu, S. et al. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol. Cancer Ther. 12, 1665-1675 (2013).
36. Schnitt, S. J. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol. 23, S60-S64 (2010).
37. Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507-516 (2013).
38. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
39. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
40. Koboldt, D. C., Larson, D. E. & Wilson, R. K. Using VarScan 2 for germline variant calling and somatic mutation detection. Curr. Protoc. Bioinformatics 44, 15.4.1-15.4.17 (2013).
41. Koboldt, D. C. et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283-2285 (2009).
42. McCormick, R. F., Truong, S. K. & Mullet, J. E. RIG: Recalibration and interrelation of genomic sequence data with the GATK. G3 (Bethesda) 5, 655-665 (2015).
43. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).
44. Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).
45. Wang, K. et al. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Res. 38, e178 (2010).
46. Mertins, P. et al. Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol. Cell Proteomics 13, 1690-1704 (2014).
47. Ellis, M. J. et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 3, 1108-1112 (2013).
48. Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteomics 13, 2513-2526 (2014).
49. Tabb, D. L. et al. Reproducibility of differential proteomic technologies in CPTAC fractionated xenografts. J Proteome Res. 15, 691-706 (2016).
50. Mertins, P. et al. Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat. Methods 10, 634-637 (2013).
51. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).